Biotech startup Biostate AI has raised $12 million in a Series A funding round led by Accel.
Gaingels, Mana Ventures, and InfoEdge Ventures joined this funding round with existing investors Matter Venture Partners, Vision Plus Capital, and Catapult Ventures.
The AI startup will use the new funding to make precision medicine easier to access, beginning with RNA sequencing (RNAseq) services for molecular research in the US.
“Rather than solve the diagnostics and therapeutics as separate, siloed problems for each disease, we believe that the modern and future AI can be a general purpose to understand and help cure every disease. Every diagnostic I’ve built was about moving the answer closer to the patient. Biostate takes the biggest leap yet by making the whole transcriptome affordable,” said Zhang, Co-founder and CEO of Biostate AI.
“Just as ChatGPT transformed language understanding by learning from trillions of words, we’re learning the molecular language of human disease from billions of RNA expressions from millions of samples. We’re doing for molecular medicine what large language models did for text—scaling the raw data so the algorithms can finally shine,” said Gopinath, Co-founder and CTO of Biostate AI and a former MIT assistant professor.
“Biostate is building the foundation model for molecular medicine by pairing deep wet lab innovation with AI to unlock RNAseq at unprecedented scale and affordability. Just as OpenAI used massive datasets to decode language, Biostate is decoding the molecular signals that govern human health,” said Shekhar Kirani, Partner at Accel.
About Biostate AI
Biostate AI, founded in 2023 by David Zhang and Ashwin Gopinath, is based in Houston, Texas. Using RNA sequencing data, the company uses generative AI to predict how diseases will develop and how patients will react to treatments.
The company is working on making RNA sequencing simpler and cheaper and creating AI models to help doctors make better decisions. By combining lab methods with AI, Biostate AI wants to reduce costs, simplify processes, and help researchers create reliable, high-quality data on a larger scale.
Biostate AI has raised over $20 million and is expanding its customer base with over 100 pilot projects focused on various diseases, such as leukemia (with Cornell) and multiple sclerosis (with the Accelerated Cure Project).
Since starting its services six months ago, the company has processed over 10,000 RNA sequencing samples for more than 150 partners and clients.
Read more- Misfits Secures ₹5 Crore In Seed Round For Further Expansion
